Ethema Files Q1 2025 Quarterly Results
MWN-AI** Summary
Ethema Health Corporation (OTC: GRST) announced its Q1 2025 results on October 17, 2025, following delays from an extensive audit review. The company anticipates completing its Q2 and Q3 2025 results within the next 30 to 45 days, which will restore its trading status on the OTC market.
For Q1 2025, Ethema reported significant revenue growth, jumping from $1.300 million to $3.518 million. This surge included $2.802 million from the recently acquired Aria Kentucky operations, alongside a 10.5% increase in revenue from its Florida facilities, totaling $1.437 million. The Boca Raton facility, acquired in May 2024, contributed to this increase after overcoming licensing delays.
Operating expenses rose substantially from $1.529 million to $4.165 million, driven primarily by personnel costs, which soared from $0.727 million to $2.063 million due to staffing in both the Kentucky and Florida facilities. Rental expenses also increased due to new facilities in Kentucky, while patient-related costs rose with the growing patient counts. The hiring increases and operational costs led to a widened operating loss, which climbed from $0.229 million to $0.647 million.
Despite rising losses, cash flow used in operations improved from $0.106 million to $0.073 million, indicating an encouraging trend given the company’s expansion activities. Interest expenses increased due to the liabilities from the Aria acquisition, although Ethema plans to refinance some of this debt with equity and more affordable banking options.
Looking forward, Ethema expects a revenue boost in Q2 and Q3, with an estimated 40% increase from Q1 to Q2 and an additional 10% increase from Q2 to Q3. CEO Shawn Leon indicated that facility capacities are nearing maximum, with further expansions anticipated to enhance profitability.
MWN-AI** Analysis
Ethema Health Corporation's Q1 2025 results reveal a compelling but nuanced picture of the company’s growth trajectory as it navigates recent acquisitions and operational challenges. Revenue surged to $3.518 million from $1.300 million, significantly driven by the newly acquired Aria Kentucky operations. This substantial growth underscores the company’s commitment to expanding its footprint in the behavioral healthcare sector. However, the surge in revenue is tempered by a notable increase in operating expenses, which climbed to $4.165 million from $1.529 million, primarily due to elevated personnel costs and operational overhead in the new facilities.
Investors should closely monitor Ethema’s ability to translate increased revenues into profitability, as the operating loss rose to $0.647 million. Despite this, the decrease in cash flow utilized in operations from $0.106 million to $0.073 million is a positive indicator, suggesting improved operational efficiency amid growth. With a projected 40% revenue increase from Q1 to Q2 and a further 10% growth expected from Q2 to Q3, there is a strong possibility for a turnaround towards profitability in the near term.
Moreover, Ethema’s plans to upgrade its debts with more favorable financing options could further alleviate financial strain as it expands operations. The company's increased patient capacity and its ongoing enhancements to operational efficiencies signify potential long-term gains.
As Ethema prepares to restore its trading status on the OTC-ID market, investors might consider positioning themselves to benefit from anticipated revenue growth and enhanced operational efficiencies. However, they should remain cautious of the operational losses and the ongoing integration challenges associated with the recent acquisitions. Balancing the potential for profitability against these risks will be pivotal in making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WEST PALM BEACH, FL - October 17, 2025 (NEWMEDIAWIRE) - Ethema Health Corporation (OTC: GRST) (“Ethema” or the “Company”), released its Q1 2025 results today after experiencing significant audit review related delays and expects to get Q2 2025 and Q3 2025 reviewed within the next 30 to 45 days. Once these reviews are completed and filed, we will restore our trading status on the OTC-ID market.
2025 Q1 Results
Our Q1 2025 results included our recently acquired Aria Kentucky operations from January 9, 2025.
Overall revenue grew from $1.300 million to $3,518 million, including $2.802 million from Aria Kentucky and existing revenue from our Florida operations grew by 10.5% to $1.437 million. Existing revenue included revenue from our Boca Raton facility, which was acquired in May 2024, for the first time, after licensing delays.
Our operating expenses have increased significantly from $1.529 million to $4.165 million. The most significant component of this cost is our personnel cost which has increased from $0.727 million to $2,063 million, of which $1.178 million relates to Aria Kentucky. The remaining increase of $0.885 million relates to our Florida operations which includes a full complement of staff at our Boca Raton facility, with revenue ramping up in this facility.
Rental expense has also increased significantly from $0.265 million to $0.740 million, primarily due to rental expense of $0.353 million incurred on our Kentucky facilities, the remaining increase of $0.122 million is primarily related to our Boca Raton facility. The Aria Kentucky and the Boca Raton facility have significant bed capacity, which gives us the opportunity to increase our customer count, improving our revenues and operating efficiency.
We have also seen an increase in patient related expenses, such as food and utility expenses in our facilities. As we increase our patient count and understand the operating costs of our newly acquired Kentucky operations and our Boca Raton facility we expect operational efficiencies to improve dramatically.
We also saw an increase in professional fees, primarily once off and deal related which impacted our operational expenses for Q1 2025.
The increased operating expenses offset our increased revenues resulting in an operating loss increasing from $0.229 million to $0.647 million, however we are confident that our increased revenues and improved operating efficiencies will result in a turnaround to operating income in the near term.
Although we saw an increase in operating losses, our cash flow utilized in operations decreased from $0.106 million to $0.073 million, which is verry encouraging in light of the significant acquisition and the launch of the Boca Raton facility.
Our interest expense and debt discount expense increased from a combined $0.156 million to $0.428 million. The increase is primarily due to the interest bearing assumed liabilities and debt funding used to acquire the assets in Aria Kentucky, however we anticipate replacing some expensive debt in both our Aria Kentucky operations and our Florida operations with a combination of equity and cheaper banking relationship funding.
We will show very significant revenue increases in Q2 and Q3 when those quarters are filed in the near future. The revenue increase from Q1 to Q2 will be approximately 40% and the revenue increase from Q2 to Q3 will be another approximately 10%.
SEC Filings and Operational Updates
We believe that we have addressed with our auditors the significant delays experienced in our 2024 year-end and subsequent Q1 2025 process and expect our Q2 2025 and Q3 2025 to be completed in the very near term. The Q2 financials are complete and will be reviewed immediately after the filing of our Q1 report. The company will restore its trading status on the OTC-ID market as soon as its filings are up to date.
Mr. Shawn Leon, our CEO, reported that “the Florida facilities operated at near capacity in July and the Kentucky facilities continue to increase its patient census and reached maximum capacity in its currently online residential facilities in August. An additional facility in Paducah, Kentucky was brough online in August and the Company expects to bring another dormant residential facility in Morehead, Kentucky online in November. This would leave only one dormant residential facility to bring online in Morehead before bringing its last residential facility, which has been temporarily used as the Kentucky head office, back on-line. Construction is underway on the ARIA Kentucky new head office in Morehead and is expected to be completed in December 2025”.
Mr. Leon added that “we are delighted to be integrating the significant Kentucky operations, which has gone very smoothly, and is attributable to our very dedicated teams in Florida and Kentucky. The Joint Commission audit in Florida was one of our best ever results for an accrediting audit and I am very proud of the Florida team for that accomplishment. The new Kentucky entity will be going through its first CARF accreditation audit at the end of October. We will continue to optimize the Florida and Kentucky assets and increase our patient count in our facilities, which will improve our profitability prospects.”
About Ethema Health Corporation
Ethema Health Corporation (OTCPINK: GRST) operates in the behavioral healthcare space specifically in the treatment of substance use disorders. Ethema developed a unique style of treatment over the last decade and has had much success with in-patient treatment for adults. Ethema will continue to develop world class programs and techniques for North America. For more information you can visit our website at www.ethemahealth.com.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For information please contact:
Ethema Health Corporation
shawn@ethemahealth.com
Text to 416-500-0020
Twitter @healthethema
View the original release on www.newmediawire.com
FAQ**
How has the recent growth in revenue for Ethema Health Corp GRST impacted the operational capacity of its facilities in West Palm Beach and Boca Raton, FL?
Given the significant operating loss reported by Ethema Health Corp GRST, what measures are being implemented to improve profitability in its Florida operations moving forward?
What factors contributed to the increase in personnel costs at Ethema Health Corp GRST's Florida facilities, and how does this align with the company's growth strategy in the region?
As Ethema Health Corp GRST anticipates a 40% revenue increase in Q2 2025, what specific strategies are in place to capitalize on this growth within the West Palm Beach market?
**MWN-AI FAQ is based on asking OpenAI questions about Ethema Health Corp (OTC: GRST).
NASDAQ: GRST
GRST Trading
33.33% G/L:
$0.0004 Last:
2,599,448 Volume:
$0.0003 Open:
